Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Go back to Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
(NASDAQ: NVCT) Delayed: 20.70 +0.11 (0.53%)
Previous Close $20.59    52 Week High $ 
Open $20.63    52 Week Low $ 
Day High $21.72    P/E N/A 
Day Low $19.94    EPS $ 
Volume 203,582